Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Single Batch Bioequivalence Paradigm for Orally Inhaled Products: Time for Change.

Hermann R, Olsson B, Borgström L, Sandell D.

Clin Pharmacol Ther. 2018 Mar;103(3):395. doi: 10.1002/cpt.939. Epub 2017 Dec 14. No abstract available.

PMID:
29238955
2.

Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.

Olsson B, Borgström L, Lundbäck H, Svensson M.

J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):355-69. doi: 10.1089/jamp.2012.0986. Epub 2013 Feb 19.

PMID:
23421897
3.

Developing and advancing dry powder inhalation towards enhanced therapeutics.

Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, Urbanetz N, Cittero M, Schoubben A, Hippchen C, Cade D, Fuglsang A, Morais J, Borgström L, Farshi F, Seyfang KH, Hermann R, van de Putte A, Klebovich I, Hincal A.

Eur J Pharm Sci. 2013 Jan 23;48(1-2):181-94. doi: 10.1016/j.ejps.2012.10.021. Epub 2012 Nov 7. Review.

PMID:
23142635
4.

Deposition, imaging, and clearance: what remains to be done?

Scheuch G, Bennett W, Borgström L, Clark A, Dalby R, Dolovich M, Fleming J, Gehr P, Gonda I, O'Callaghan C, Taylor G, Newman S.

J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S39-57. doi: 10.1089/jamp.2010.0839. Review.

PMID:
21133799
5.

Introduction. 1000 years of pharmaceutical aerosols: what remains to be done?

Borgström L, Clark A, Olsson B.

J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S1-4. doi: 10.1089/jamp.2010.0848. No abstract available.

PMID:
21133797
6.
7.

Use of dry powder inhalers in acute exacerbations of asthma and COPD.

Selroos O, Borgström L, Ingelf J.

Ther Adv Respir Dis. 2009 Apr;3(2):81-91. doi: 10.1177/1753465809103737. Epub 2009 May 14. Review.

PMID:
19443520
8.

Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.

Tronde A, Gillen M, Borgström L, Lötvall J, Ankerst J.

J Clin Pharmacol. 2008 Nov;48(11):1300-8. doi: 10.1177/0091270008322122.

PMID:
18974284
9.

Sustained mechanical and clinical functionality of the flexhaler dry powder inhaler.

Lööf T, Elfman P, Ström P, Törngren A, Borgström L.

J Aerosol Med Pulm Drug Deliv. 2008 Dec;21(4):381-8. doi: 10.1089/jamp.2008.0700.

PMID:
18823260
10.

Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults.

Eklund A, Tronde A, Johannes-Hellberg I, Gillen M, Borgström L.

Biopharm Drug Dispos. 2008 Oct;29(7):382-95. doi: 10.1002/bdd.622.

PMID:
18623040
11.

Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?

Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J.

Pulm Pharmacol Ther. 2008;21(2):247-58. Epub 2007 Sep 6. Review.

PMID:
17950641
12.

Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV--the oropharyngeal retention effect for four inhalation delivery systems.

Burnell PK, Asking L, Borgström L, Nichols SC, Olsson B, Prime D, Shrubb I.

J Aerosol Med. 2007 Fall;20(3):269-81.

PMID:
17894534
13.

Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.

Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R.

Respir Med. 2007 Sep;101(9):1931-41. Epub 2007 Jun 1.

14.

Degree of throat deposition can explain the variability in lung deposition of inhaled drugs.

Borgström L, Olsson B, Thorsson L.

J Aerosol Med. 2006 Winter;19(4):473-83.

PMID:
17196076
16.

Idealhalers or realhalers? A comparison of Diskus and Turbuhaler.

Borgström L, Asking L, Thorsson L.

Int J Clin Pract. 2005 Dec;59(12):1488-95. Review.

PMID:
16351685
17.

An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions.

Borgström L, Asking L, Lipniunas P.

J Aerosol Med. 2005 Fall;18(3):304-10.

PMID:
16181005
18.

Dose delivery late in the breath can increase dry powder aerosol penetration into the lungs.

Bondesson E, Bengtsson T, Borgström L, Nilsson LE, Norrgren K, Olsson B, Svensson M, Wollmer P.

J Aerosol Med. 2005 Spring;18(1):23-33.

PMID:
15741771
19.

Planar gamma scintigraphy--points to consider when quantifying pulmonary dry powder aerosol deposition.

Bondesson E, Bengtsson T, Borgström L, Nilsson LE, Norrgren K, Trofast E, Wollmer P.

Int J Pharm. 2003 Jun 4;258(1-2):227-40.

PMID:
12753769
20.

Planar gamma scintigraphy--points to consider when quantifying pulmonary dry powder aerosol deposition.

Bondesson E, Bengtsson T, Borgström L, Nilsson LE, Norrgren K, Trofast E, Wollmer P.

Int J Pharm. 2003 Jan 30;251(1-2):33-47. Corrected and republished in: Int J Pharm. 2003 Jun 4;258(1-2):227-40.

PMID:
12527173
21.

In vitro and in vivo aspects of quantifying intrapulmonary deposition of a dry powder radioaerosol.

Bondesson E, Asking L, Borgström L, Nilsson LE, Trofast E, Wollmer P.

Int J Pharm. 2002 Jan 31;232(1-2):149-56.

PMID:
11790498
22.

Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals.

Derom E, Borgström L, Van Schoor J, Löfroos AB, Pauwels R.

Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1398-402.

PMID:
11704585
23.

On the use of dry powder inhalers in situations perceived as constrained.

Borgström L.

J Aerosol Med. 2001 Fall;14(3):281-7. Review.

PMID:
11693839
24.

Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate.

Walker PS, Conway JH, Fleming JS, Bondesson E, Borgström L.

J Aerosol Med. 2001 Summer;14(2):209-15.

PMID:
11681652
25.

The importance of the device in asthma therapy.

Borgström L.

Respir Med. 2001 Aug;95 Suppl B:S26-9.

26.
27.

Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma.

Fishwick D, Bradshaw L, Macdonald C, Beasley R, Gash D, Bengtsson T, Bondesson E, Borgström L.

Am J Respir Crit Care Med. 2001 Feb;163(2):474-7.

PMID:
11179125
28.
29.

The pharmacokinetics of inhaled hydrofluoroalkane formulations.

Borgström L.

J Allergy Clin Immunol. 1999 Dec;104(6):S246-9.

PMID:
10588984
30.

In vitro, ex vivo, in vivo veritas.

Borgström L.

Allergy. 1999;54 Suppl 49:88-92.

PMID:
10422754
31.

Lung deposition of budesonide from turbuhaler in asthmatic children.

Wildhaber JH, Devadason SG, Wilson JM, Roller C, Lagana T, Borgström L, LeSouëf PN.

Eur J Pediatr. 1998 Dec;157(12):1017-22.

PMID:
9877044
32.
33.

The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients.

Kenyon CJ, Thorsson L, Borgström L, Newman SP.

Eur Respir J. 1998 Mar;11(3):606-10.

34.

Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler.

Borgström L, Asking L, Beckman O, Bondesson E, Källén A, Olsson B.

J Aerosol Med. 1998;11 Suppl 1:S59-64. No abstract available.

PMID:
10180734
35.

Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers.

Pauwels R, Newman S, Borgström L.

Eur Respir J. 1997 Sep;10(9):2127-38. Review.

36.

Lung deposition from the Turbuhaler in children with cystic fibrosis.

Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, Borgstrom L, Le Souëf PN.

Eur Respir J. 1997 Sep;10(9):2023-8.

37.

The inhalation device influences lung deposition and bronchodilating effect of terbutaline.

Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R.

Am J Respir Crit Care Med. 1996 May;153(5):1636-40.

PMID:
8630614
39.

The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum.

Fagerholm U, Borgström L, Ahrenstedt O, Lennernäs H.

J Drug Target. 1995;3(3):191-200.

PMID:
8705252
40.

Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.

Borgström L, Bondesson E, Morén F, Trofast E, Newman SP.

Eur Respir J. 1994 Jan;7(1):69-73.

41.

Deposition patterns with Turbuhaler.

Borgström L.

J Aerosol Med. 1994;7(Suppl 1):S49-53.

PMID:
10147081
42.
43.

Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods.

Borgström L, Newman S, Weisz A, Morén F.

J Pharm Sci. 1992 Aug;81(8):753-5.

PMID:
1403719
44.

Exercise increases the rate of pulmonary absorption of inhaled terbutaline.

Schmekel B, Borgström L, Wollmer P.

Chest. 1992 Mar;101(3):742-5.

PMID:
1541141
45.
46.
47.

Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man.

Borgström L, Kågedal B.

Biopharm Drug Dispos. 1990 Mar;11(2):131-6.

PMID:
2328298
48.

Relative absorption of the two enantiomers of terbutaline after duodenal administration.

Borgström L, Kennedy BM, Nilsson B, Angelin B.

Eur J Clin Pharmacol. 1990;38(6):621-3.

PMID:
2373137
49.

Absolute bioavailability of terbutaline from a CR-granulate in asthmatic children.

Fuglsang G, Hertz B, Holm EB, Borgström L.

Biopharm Drug Dispos. 1990 Jan-Feb;11(1):85-90.

PMID:
2322639
50.

Dose-response relationships of intravenously administered terbutaline in children with asthma.

Fuglsang G, Pedersen S, Borgström L.

J Pediatr. 1989 Feb;114(2):315-20.

PMID:
2915294

Supplemental Content

Loading ...
Support Center